Raloxifene Hydrochloride CAS:82640-04-8
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- China
- Payment Terms
- MoneyGram,Others,T/T,Western Union
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- amino acid, nutrient, raloxifene hcl, labeled raloxifene
- Category
- Pharmaceutical Intermediates
Chongqing Tingyi Biotechnology Co.,Ltd
China
- Verified Certificate
-
6
| Product name | Raloxifene Hydrochloride CAS:82640-04-8 | Certification | - |
|---|---|---|---|
| Category | Pharmaceutical Intermediates | Ingredients | - |
| Keyword | amino acid , nutrient , raloxifene hcl , labeled raloxifene | Unit Size | - |
| Brand name | - | Unit Weigh | 1 kg |
| origin | China | Stock | - |
| Supply type | - | HS code | - |
Product Information
Raloxifene Hydrochloride CAS:82640-04-8
Product Name: Raloxifene Hydrochloride
Synonyms: Raloxifene HCL
CAS: 82640-04-8
MF: C28H28ClNO4S
MW: 510.04
mp: 250-253°C
storage temp: -20°C Freezer
solubility DMSO: 28 mg/mL, soluble
appearance: Light-Yellow Solid
Usage:
1.Amino acid, nutrient
2.Labeled Raloxifene, intended for use as an internal standard for the quantification of Raloxifene by GC- or LC-mass spectrometry.
3.A nonste roidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Application:
May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticoster oid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | MoneyGram,Others,T/T,Western Union | Shipping time | Negotiable |
- President
- Mr.lee
- Address
- Yubeiblock,Chongqin city
- Product Category
- Pharmaceutical Intermediates
- Year Established
- 2003
- No. of Total Employees
- 501-1000
- Company introduction
-
- Main Markets
-
Belgium
Canada
France
Germany
Ireland
Italy
U. Kingdom
U.S.A
- Main Product
